Madrigal Pharmaceuticals, Inc.

NASDAQ:MDGL

Biotechnology

Healthcare
$398.08 -0.27%

-$1.33 today

Market cap
$9.25B
Beta
-1.06
P/E (TTM)
-46.9
EPS (TTM)
-$10.66
52W Low $276.67High $615.00

Volume 0.64M

Average 0.31M

MDGL Investing Cash Flow

Net cash used in or generated by investments in assets, acquisitions, and securities.

Madrigal Pharmaceuticals, Inc.NASDAQ: MDGL

Investing Cash Flow · Q2 FY2026 · quarter ended Jun 2026

Investing cash flow dips below year-ago levels

Q2 FY2026 investing cash flow of $34.2M fell 28.5% year over year, behind the +221.7% change in trailing-twelve-month investing cash flow. Sequentially, it fell 82.2% from the prior quarter. Over 3 fiscal years it compounded at -46.1% a year.

Context

  • Investing cash flow amounted to 3.4% of revenue in FY2025, down 149.0 pp from a year earlier.
  • Investing cash flow increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from -28.5% toward the trailing-twelve-month pace of +221.7%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2026
$34.2M-82.2% QoQ
Last fiscal yearDec 2025
$32.32M+111.8% YoY
LTMJun 2026
$46.97M+221.7% YoY
Investing Cash Flow past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-28.5%——
1 year+111.8%——
3-year CAGR-46.1%——
5-year CAGR——
10-year CAGR——

Investing Cash Flow history

USD · from the cash flow

Latest · FY2025
32.32M USD
Year-over-year change
+111.8%

Investing Cash Flow vs competitors

How MDGL compares with its peers on the latest reported figures

  • Peers report in different currencies, so investing cash flow is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +221.7% is the 2nd highest of 7, against a peer median of +17.3%.
  • Investing cash flow amounts to 3.7% of revenue for MDGL, versus a peer median of 1837.8%.
MDGL Competitors
Investing Cash Flow for MDGL and competitors
Company Period LTM YoY 3-year CAGR% of revenue
VKTXViking Therapeutics, Inc.LTM Jun 2026$399.26M USD+188.8%+84.1%—
MAZEMaze Therapeutics, Inc.LTM Mar 2026$164.39M USD+13986.4%+277.8%821.9%
ALTAltimmune, Inc.LTM Mar 2026$131.06M USD-2272.1%+21.8%364061.1%
IVAInventiva S.A.FY2025€127.93M EUR-1562.9%—2853.7%
MDGLMadrigal Pharmaceuticals, Inc.LTM Jun 2026$46.97M USD+221.7%-46.1%3.7%
NAMSNewAmsterdam Pharma Company N.V.LTM Jun 2026$34.91M USD-84.0%+825.0%490.2%
SGMTSagimet Biosciences Inc.LTM Mar 2026$11.36M USD+118.5%——
Peer median (excluding MDGL) —+17.3%+180.9%1837.8%

Competitors are the stored peer set for MDGL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(241.85M)(295.35M)(373.63M)(465.89M)(288.28M)
Depreciation & Amortization405K467K527K1.1M1.51M
Deferred Income Tax(7.32M)0000
Stock-Based Compensation26.87M31.63M49.74M79.88M98.13M
Change in Working Capital30.65M37.6M(3.28M)(72.35M)(8.5M)
Accounts Receivables000(53.82M)(80.65M)
Inventory000(34.07M)(36.98M)
Accounts Payables20.36M2.45M4.21M15.56M5.28M
Other Working Capital10.29M35.15M(7.49M)(13K)103.86M
Other Non-Cash Items7.32M797K2.41M1.69M7.59M
Operating Cash Flow(183.92M)(224.86M)(324.23M)(455.57M)(189.55M)
Capital Expenditures(209K)(217K)(1.48M)(1.46M)(467K)
Acquisitions (Net)787K(3K)000
Purchases of Investments(394.12M)(143.48M)(834.44M)(1.13B)(1.05B)
Sales of Investments389.27M350.38M333.4M839.19M1.09B
Other Investing Activities(787K)3K019.09M(8.97M)
Investing Cash Flow(5.06M)206.69M(502.52M)(274.39M)32.32M
Debt Repayment050M65M0217.93M
Common Stock Issued170.21M255.38M260.19M397.49M38.06M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities1.03M8.07M269.93M337.58M0
Financing Cash Flow171.24M313.45M595.12M735.06M255.98M
Effect of Forex Changes000013K
Net Change in Cash(17.74M)295.28M(231.63M)5.1M98.76M
Free Cash Flow(184.13M)(225.07M)(325.71M)(457.03M)(190.02M)

Madrigal Pharmaceuticals, Inc.

NASDAQ:MDGL

Intrinsic Alpha fair value

Locked

Current Price

$398.08

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.